Does Cannabis Impact Sleep Architecture in Sleep Apnoea?
Posted
Updated
Author: Julia Sutton, MSc
Reviewed by: Dr. Clarissa Morton, PharmD
Sleep architecture refers to the structured cycle of REM and NREM stages that make up healthy rest. Understanding the impact of cannabis on sleep architecture is important for patients with sleep apnoea , as disruptions in these stages can worsen symptoms and overall wellbeing.
Research suggests the impact of cannabis on sleep architecture may include changes in both REM NREM with cannabis, with potential alterations in the depth and duration of each sleep phase.
REM Sleep Effects
Studies show that cannabis can reduce REM duration. This means the impact of cannabis on sleep architecture may lower dream-related sleep while potentially supporting deeper non-REM stages.
NREM Sleep Considerations
The role of REM NREM with cannabis is critical, as non-REM sleep supports physical restoration. Cannabis might help stabilise NREM cycles in some patients, improving sleep staging in OSA.
Clinical Implications
Changes in sleep staging in OSA can directly affect breathing stability. While certain shifts may benefit apnoea outcomes, excessive suppression of REM stages could also present concerns.
The impact of cannabis on sleep architecture remains an evolving area of study. Early findings suggest possible modulation of REM NREM with cannabis, but more robust trials are required to define safe and effective use in sleep apnoea management.
If you’re exploring cannabis treatment options for obstructive sleep apnoea, visit providers like LeafEase for personalised consultations and guidance tailored to your needs.
For a deeper dive into the science, diagnosis, and full treatment landscape, read our complete guide to Medical Cannabis and Obstructive Sleep Apnoea .
Written by
Julia Sutton, MSc
Julia Sutton is a clinical psychologist with a Master’s in Clinical Psychology and experience providing psychological assessment and therapy to adolescents and adults. Skilled in CBT, client-centered therapy, and evidence-based interventions, she has worked with conditions including depression, anxiety, bipolar disorder, and conversion disorder. She also has experience in child psychology, conducting psycho-educational evaluations and developing tailored treatment plans to improve learning and well-being.
All qualifications and professional experience stated above are authentic and verified by our editorial team. However, pseudonym and image likeness are used to protect the author's privacy.
Reviewed by
Dr. Clarissa Morton, PharmD
Dr. Clarissa Morton is a licensed pharmacist with a Doctor of Pharmacy degree and experience across hospital, community, and industrial pharmacy. She has worked in emergency, outpatient, and inpatient pharmacy settings, providing patient counseling, dispensing medications, and ensuring regulatory compliance. Alongside her pharmacy expertise, she has worked as a Support Plan & Risk Assessment (SPRA) officer and in medical coding, applying knowledge of medical terminology, EMIS, and SystmOne software to deliver accurate, compliant healthcare documentation. Her skills span medication safety, regulatory standards, healthcare data management, and statistical reporting.
All qualifications and professional experience stated above are authentic and verified by our editorial team. However, pseudonym and image likeness are used to protect the reviewers's privacy.
